Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

The drugmaker is divesting Takeda Consumer Healthcare, which operates mainly in Japan, to private equity group Blackstone for 242 billion yen ($2.3 billion), with the deal expected to close in ...

At an extraordinary general meeting held in Osaka, 88% of Takeda’s shareholders voted in favour of the deal and allowed Weber’s team to go ahead and close it in early January.

Takeda’s CEO Christophe Weber got the deal across the line despite protests from a small but vocal group of shareholders concerned about repaying the bank loan of more than $30 billion needed to ...

Takeda has decided that there is a future for its aurora kinase A inhibitor alisertib after it failed a phase 3 trial in lymphoma – but the company won't be taking the drug forward itself. Enter ...

A pioneering clinical trial backed by the EU and drugmaker Takeda will look for biomarkers that could be used to identify people at risk of developing Crohn's disease in the hope of intervening ...

Takeda completed $7 billion of divestments in 2019, including assets in the Middle East and Africa. It also sold the dry-eye drug Xiidra, originally developed by Shire for $5.3 billion to Novartis.

South Korea’s Celltrion has made its first major acquisition, buying a portfolio of drugs including diabetes and hypertension drugs from Takeda that will expand its expertise with small ...

Takeda has made a strong play for a stake in the Alzheimer’s disease market, paying $100 million upfront for an option on AC Immune’s amyloid-targeting immunotherapy. The option fee could be ...